Opexa Therapeutics Stock Price, News & Analysis (NASDAQ:ACER)

$11.81 -0.09 (-0.76 %)
(As of 12/15/2017 01:11 AM ET)
Previous Close$11.90
Today's Range$11.81 - $12.01
52-Week Range$5.69 - $22.63
Volume21,469 shs
Average Volume33,857 shs
Market Capitalization$77.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26

About Opexa Therapeutics (NASDAQ:ACER)

Opexa Therapeutics logoAcer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.11%
Quick Ratio4.11%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.90 million
Price / Sales26.27
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book3.02

Profitability

Trailing EPS($5.75)
Net Income$-7,970,000.00
Net MarginsN/A
Return on Equity-170.41%
Return on Assets-146.90%

Miscellaneous

Employees36
Outstanding Shares6,450,000

Opexa Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Opexa Therapeutics' stock symbol?

Opexa Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Opexa Therapeutics' earnings last quarter?

Opexa Therapeutics, Inc. (NASDAQ:ACER) released its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter. View Opexa Therapeutics' Earnings History.

Who are some of Opexa Therapeutics' key competitors?

Who are Opexa Therapeutics' key executives?

Opexa Therapeutics' management team includes the folowing people:

  • Christopher Schelling, President, Chief Executive Officer, Director
  • Harry S. Palmin, Chief Financial Officer
  • William T. Andrews, Chief Medical Officer
  • Jason Amello, Director
  • , Bio & Compensation - 
  • Stephen J. Aselage, Director
  • , Bio & Compensation - 
  • Hubert Birner, Director
  • , Bio & Compensation - 
  • John M. Dunn, Director
  • , Bio & Compensation - 
  • Michelle Griffin, Director
  • , Bio & Compensation - 

How do I buy Opexa Therapeutics stock?

Shares of Opexa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opexa Therapeutics' stock price today?

One share of Opexa Therapeutics stock can currently be purchased for approximately $11.81.

How big of a company is Opexa Therapeutics?

Opexa Therapeutics has a market capitalization of $77.35 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-7,970,000.00 in net income (profit) each year or ($5.75) on an earnings per share basis. Opexa Therapeutics employs 36 workers across the globe.

How can I contact Opexa Therapeutics?

Opexa Therapeutics' mailing address is 222 THIRD STREET SUITE 2240, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Opexa Therapeutics (ACER)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Opexa Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Opexa Therapeutics (NASDAQ:ACER) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.67$11.67$11.67$11.67
Price Target Upside: 243.14% upside243.14% upside243.14% upside243.14% upside

Opexa Therapeutics (NASDAQ:ACER) Consensus Price Target History

Price Target History for Opexa Therapeutics (NASDAQ:ACER)

Opexa Therapeutics (NASDAQ:ACER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2016Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
10/28/2016Chardan CapitalDowngradeBuy -> NeutralN/AView Rating Details
10/28/2016AegisDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Opexa Therapeutics (NASDAQ:ACER) Earnings History and Estimates Chart

Earnings by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Opexa Therapeutics (NASDAQ ACER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($1.09)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.12)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.25)($0.28)$0.73 millionViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)$0.73 million$0.73 millionViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)$0.73 million$0.73 millionViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)$0.73 million$0.73 millionViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)$0.73 million$0.73 millionViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)$0.73 millionViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)$0.38 millionViewListenView Earnings Details
11/6/2014($0.14)($0.12)$0.30 million$0.31 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)$0.30 million$0.31 millionViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Opexa Therapeutics (NASDAQ:ACER) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Opexa Therapeutics (NASDAQ:ACER)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Opexa Therapeutics (NASDAQ ACER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.88%
Institutional Ownership Percentage: 0.28%
Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Opexa Therapeutics (NASDAQ ACER) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.70View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Opexa Therapeutics (NASDAQ ACER) News Headlines

Source:
DateHeadline
Acer Therapeutics Announces Closing of Underwritten Public Offering of Common StockAcer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
finance.yahoo.com - December 14 at 6:28 PM
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common StockAcer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
finance.yahoo.com - December 11 at 6:11 PM
 Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Analysts Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 10 at 5:18 PM
Opexa Therapeutics (ACER) and The Competition Critical ComparisonOpexa Therapeutics (ACER) and The Competition Critical Comparison
www.americanbankingnews.com - December 7 at 1:16 PM
Reviewing Opexa Therapeutics (ACER) and Its RivalsReviewing Opexa Therapeutics (ACER) and Its Rivals
www.americanbankingnews.com - November 29 at 3:20 PM
Zacks: Opexa Therapeutics, Inc. (ACER) Receives Average Rating of "Hold" from AnalystsZacks: Opexa Therapeutics, Inc. (ACER) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 18 at 3:37 AM
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - November 14 at 3:54 PM
Acer Therapeutics Inc. (ACER) Releases Quarterly  Earnings ResultsAcer Therapeutics Inc. (ACER) Releases Quarterly Earnings Results
www.americanbankingnews.com - November 14 at 8:20 AM
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateAcer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 13 at 6:05 PM
Comparing Opexa Therapeutics (ACER) and Its CompetitorsComparing Opexa Therapeutics (ACER) and Its Competitors
www.americanbankingnews.com - November 9 at 1:12 AM
Comparing Redhill Biopharma (RDHL) & Opexa Therapeutics (ACER)Comparing Redhill Biopharma (RDHL) & Opexa Therapeutics (ACER)
www.americanbankingnews.com - October 23 at 10:58 AM
Reviewing Opexa Therapeutics (ACER) and La Jolla Pharmaceutical (LJPC)Reviewing Opexa Therapeutics (ACER) and La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - October 21 at 6:38 AM
Acer Therapeutics (ACER) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowAcer Therapeutics (ACER) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - October 18 at 3:40 PM
Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical OfficerAcer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer
finance.yahoo.com - October 5 at 12:35 PM
 Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Brokerages Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 1 at 10:44 AM
Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceAcer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 12:13 PM

SEC Filings

Opexa Therapeutics (NASDAQ:ACER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Opexa Therapeutics (NASDAQ:ACER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Opexa Therapeutics (NASDAQ ACER) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.